Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Robeco Institutional Asset Management increased its stake in Regeneron Pharmaceuticals (REGN) by 21.91% based on its latest 2018Q3 regulatory filing with the SEC. Robeco Institutional Asset Management bought 1,000 shares as the company’s stock declined 4.42% with the market. The institutional investor held 5,564 shares of the health care company at the end of 2018Q3, valued at $2.25 million, up from 4,564 at the end of the previous reported quarter. Robeco Institutional Asset Management who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $44.08B market cap company. The stock increased 2.02% or $8.07 during the last trading session, reaching $407.65. About 720,335 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 1.07% since January 10, 2018 and is uptrending. It has outperformed by 1.07% the S&P500. Some Historical REGN News: 03/05/2018 – Regeneron Pharma 1Q Net $478M; 03/04/2018 – EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA; 19/03/2018 – EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL; 23/04/2018 – Regeneron at J.P. Morgan Spring Biotech Conference May 8; 11/05/2018 – Bayer: Eylea Treats Visual Impairment From Macular Degeneration; 10/03/2018 – PRALUENT REDUCES RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 15 PCT VS PLACEBO IN MULTI-YEAR “OUTCOMES” STUDY – DATA; 29/03/2018 – Regeneron/Sanofi’s Dupixent (dupilumab) Drug Analysis 2018 – ResearchAndMarkets.com; 31/05/2018 – Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema; 10/03/2018 – Regeneron, Sanofi Cut Heart Drug’s Price as Trial Disappoints; 22/03/2018 – From the night bureau: The PCSK9 of NASH? Regeneron and Alnylam join forces to tackle a promising target for severe liver diseases

Montag & Caldwell Llc increased its stake in Activision Blizzard Inc. (ATVI) by 90.97% based on its latest 2018Q3 regulatory filing with the SEC. Montag & Caldwell Llc bought 416,231 shares as the company’s stock declined 35.52% with the market. The institutional investor held 873,795 shares of the technology company at the end of 2018Q3, valued at $72.69M, up from 457,564 at the end of the previous reported quarter. Montag & Caldwell Llc who had been investing in Activision Blizzard Inc. for a number of months, seems to be bullish on the $39.03 billion market cap company. The stock increased 0.64% or $0.32 during the last trading session, reaching $51.15. About 4.43M shares traded. Activision Blizzard, Inc. (NASDAQ:ATVI) has declined 22.23% since January 10, 2018 and is downtrending. It has underperformed by 22.23% the S&P500. Some Historical ATVI News: 16/04/2018 – Activision Blizzard Partners with Nielsen on Esports Brand Valuation; 30/04/2018 – MOODY’S UPGRADES ACTIVISION BLIZZARD INC.’S SR UNSECURED; 03/05/2018 – Activision Blizzard 1Q Rev $1.97B; 21/03/2018 – Mega-hit ‘Fortnite’ game has wiped out $6 billion in market value from industry leader Activision Blizzard; 04/05/2018 – Activision Blizzard sales hit by success of rival’s `Fortnite’; 03/05/2018 – Activision Blizzard 1Q Rev $1.7B; 22/05/2018 – Activision ‘Best Positioned’ for Coming Billion-Dollar Bonanza; 03/05/2018 – Activision Blizzard Increases CY 2018 Rev and EPS Outlook; 10/04/2018 – Call of Duty: WWII ‘The War Machine’ DLC Pack Rolls out Today; 10/04/2018 – Call of Duty: WWII `The War Machine’ DLC Pack Rolls out Today

Montag & Caldwell Llc, which manages about $14.22 billion and $2.56B US Long portfolio, decreased its stake in Facebook Inc (NASDAQ:FB) by 13,639 shares to 225,607 shares, valued at $37.10 million in 2018Q3, according to the filing. It also reduced its holding in Qualcomm Inc (NASDAQ:QCOM) by 549,838 shares in the quarter, leaving it with 623,236 shares, and cut its stake in Monster Beverage Corp.

Among 33 analysts covering Activision Blizzard (NASDAQ:ATVI), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Activision Blizzard had 146 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Monday, August 8 with “Buy”. The rating was maintained by Barclays Capital with “Overweight” on Friday, February 12. The stock of Activision Blizzard, Inc. (NASDAQ:ATVI) has “Overweight” rating given on Thursday, June 16 by Barclays Capital. Hilliard Lyons downgraded the stock to “Neutral” rating in Thursday, August 6 report. The rating was upgraded by Hilliard Lyons to “Neutral” on Wednesday, November 8. The rating was maintained by KeyBanc Capital Markets on Friday, February 9 with “Overweight”. The stock of Activision Blizzard, Inc. (NASDAQ:ATVI) has “Buy” rating given on Wednesday, January 24 by SunTrust. The stock has “Buy” rating by KeyBanc Capital Markets on Wednesday, September 6. The stock of Activision Blizzard, Inc. (NASDAQ:ATVI) earned “Outperform” rating by Wedbush on Friday, November 4. The rating was maintained by Barclays Capital with “Equal-Weight” on Friday, February 9.

Since August 16, 2018, it had 0 buys, and 1 sale for $1.36 million activity.

Investors sentiment increased to 1.57 in 2018 Q3. Its up 0.37, from 1.2 in 2018Q2. It improved, as 43 investors sold ATVI shares while 206 reduced holdings. 122 funds opened positions while 269 raised stakes. 663.95 million shares or 2.95% more from 644.93 million shares in 2018Q2 were reported. Baystate Wealth Ltd Company owns 210 shares. Sage Fincl Grp Inc invested in 0% or 51 shares. Norinchukin National Bank The has invested 0.11% in Activision Blizzard, Inc. (NASDAQ:ATVI). Moody Comml Bank Division owns 99,893 shares for 0.21% of their portfolio. Lourd stated it has 5,759 shares or 0.03% of all its holdings. Moreover, Northern has 0.19% invested in Activision Blizzard, Inc. (NASDAQ:ATVI). Badgley Phelps Bell owns 175,445 shares. Morgan Stanley has invested 0.46% in Activision Blizzard, Inc. (NASDAQ:ATVI). Malaga Cove Capital Lc holds 14,070 shares or 0.63% of its portfolio. Lone Pine Capital Ltd Com invested 6.91% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI). Bessemer Gru stated it has 0.38% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI). First Retail Bank Of Hutchinson holds 0.51% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI) for 10,739 shares. Truepoint Incorporated holds 0.03% or 3,816 shares in its portfolio. Brown Advisory Secs Ltd Liability Corp accumulated 2,815 shares. Clarivest Asset Mngmt Limited Liability owns 488,677 shares.

More notable recent Activision Blizzard, Inc. (NASDAQ:ATVI) news were published by: Nasdaq.com which released: “Activision Blizzard (ATVI) Gains As Market Dips: What You Should Know – Nasdaq” on December 20, 2018, also Seekingalpha.com with their article: “‘Red Dead’ online adds battle-royale mode – Seeking Alpha” published on January 10, 2019, Seekingalpha.com published: “Activision Blizzard names three veterans to leadership roles – Seeking Alpha” on January 09, 2019. More interesting news about Activision Blizzard, Inc. (NASDAQ:ATVI) were released by: Fool.com and their article: “Time to Buy Activision Blizzard Stock? 1 Analyst Thinks So – Motley Fool” published on December 04, 2018 as well as Investorplace.com‘s news article titled: “Proctor & Gamble Stock Is Out Over Its Skis As Investors Got Defensive – Investorplace.com” with publication date: December 17, 2018.

Since August 22, 2018, it had 0 insider buys, and 7 selling transactions for $46.41 million activity. 104,552 shares valued at $42.52M were sold by Sanofi on Thursday, September 6. BROWN MICHAEL S sold 2,000 shares worth $784,524. Another trade for 6 shares valued at $2,294 was made by VAGELOS P ROY on Wednesday, December 12. Another trade for 1,848 shares valued at $663,381 was sold by Fenimore Christopher R..

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “Noteworthy Wednesday Option Activity: PYPL, REGN, WMT – Nasdaq” on November 28, 2018, also Seekingalpha.com with their article: “Will Regeneron Close At $400? – Seeking Alpha” published on August 22, 2018, Investorplace.com published: “Value Investors Should Buy into the Teva Stock Dip – Investorplace.com” on December 26, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Seekingalpha.com and their article: “Why Regeneron Has 30 Percent Upside – Seeking Alpha” published on May 07, 2018 as well as Nasdaq.com‘s news article titled: “Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential – Nasdaq” with publication date: September 17, 2018.

Among 34 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 20 Hold. Therefore 38% are positive. Regeneron Pharmaceuticals Inc. had 139 analyst reports since July 28, 2015 according to SRatingsIntel. On Monday, October 16 the stock rating was maintained by BMO Capital Markets with “Hold”. The stock has “Market Perform” rating by Bernstein on Monday, June 26. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Neutral” rating by Citigroup on Friday, December 1. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, October 11 report. Goldman Sachs upgraded the shares of REGN in report on Friday, December 14 to “Buy” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Outperform” rating given on Friday, January 6 by RBC Capital Markets. The firm has “Buy” rating by Brean Capital given on Tuesday, March 8. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Piper Jaffray on Thursday, September 7. The rating was downgraded by Raymond James on Monday, April 9 to “Market Perform”. On Wednesday, August 5 the stock rating was maintained by UBS with “Sell”.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.





Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *